Last reviewed · How we verify

Azithromycin Oral Liquid Product — Competitive Intelligence Brief

Azithromycin Oral Liquid Product (Azithromycin Oral Liquid Product) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Macrolide antibiotic. Area: Infectious diseases.

phase 2 Macrolide antibiotic 50S ribosomal subunit Infectious diseases Small molecule Live · refreshed every 30 min

Target snapshot

Azithromycin Oral Liquid Product (Azithromycin Oral Liquid Product) — Copenhagen Studies on Asthma in Childhood. Azithromycin is a macrolide antibiotic that inhibits protein synthesis by binding to the 50S ribosomal subunit.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Azithromycin Oral Liquid Product TARGET Azithromycin Oral Liquid Product Copenhagen Studies on Asthma in Childhood phase 2 Macrolide antibiotic 50S ribosomal subunit
CLDM 1% gel CLDM 1% gel GlaxoSmithKline marketed Lincosamide antibiotic Bacterial 50S ribosomal subunit
Linezolid antimicrobial-lock solution Linezolid antimicrobial-lock solution Clinica Universidad de Navarra, Universidad de Navarra marketed Oxazolidinone antibiotic Bacterial 50S ribosomal subunit
linezolid (Zyvox) linezolid (Zyvox) Pfizer marketed Oxazolidinone antibiotic Bacterial 50S ribosomal subunit
Azithropycin according to symptoms Azithropycin according to symptoms University Hospital, Montpellier marketed Macrolide antibiotic Bacterial 50S ribosomal subunit (23S rRNA)
AzaSite® AzaSite® Merck Sharp & Dohme LLC marketed Macrolide antibiotic Bacterial 50S ribosomal subunit
Clarithromycin (ST14) Clarithromycin (ST14) National Taiwan University Hospital marketed Macrolide antibiotic Bacterial 50S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Macrolide antibiotic class)

  1. Pfizer · 6 drugs in this class
  2. Grünenthal GmbH · 4 drugs in this class
  3. Merck Sharp & Dohme LLC · 3 drugs in this class
  4. University of Taubate · 2 drugs in this class
  5. Lihir Medical Centre · 2 drugs in this class
  6. Thomas Jefferson University · 2 drugs in this class
  7. Copenhagen Studies on Asthma in Childhood · 1 drug in this class
  8. Ain Shams Maternity Hospital · 1 drug in this class
  9. Celltrion · 1 drug in this class
  10. London School of Hygiene and Tropical Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Azithromycin Oral Liquid Product — Competitive Intelligence Brief. https://druglandscape.com/ci/azithromycin-oral-liquid-product. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: